六基库明减轻血管光滑肌细胞中血管酶II诱导的增殖,迁移和炎症

相关实验视频

Updated: Jul 20, 2025

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function

Published on: June 11, 2017

Luckika Panthiya^1,2, Jiraporn Tocharus³, Waraluck Chaichompoo⁴

¹Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

|August 3, 2023

概括

六基库明 (HHC) 通过抑制血管光滑肌细胞增殖和炎症来保护心血管健康. 它抑制活性氧物种并增强保护性通路,为动脉样硬化和高血压提供潜在的治疗方法.

科学领域:

心血管生物学心血管生物学
分子药理学分子药理学
细胞病理生理学

背景情况:

血管光滑肌细胞 (VSMC) 的增殖和迁移是动脉样硬化和高血压的关键.
氨酸 (HHC) 是一种氨酸代谢物,显示出心血管保护潜力.

研究的目的:

研究HC对血管素II (Ang II) 诱导的VSMC增殖,迁移和炎症的影响.
阐明 HHC 的作用背后的分子机制.

主要方法:

已使用的老鼠大动脉VSMC用Ang II.治疗.
评估了VSMC的扩散,迁移,活性氧物种 (ROS) 生成和炎症标志物.
研究对细胞循环蛋白 (cyclin D1,p21),NF-κB,TNF-α,IL-6,MMP9,PPAR-γ和PGC-1α的影响.
在机理学研究中使用NADPH氧化酶抑制剂 (GKT137831).

主要成果:

HHC显著抑制了Ang II诱导的VSMC的扩散,迁移和炎症.
HHC减弱了ROS生成,并降低了NF-κB,TNF-α,IL-6和MMP9的表达.
HHC正常化了环素D1/p21表达和上调的PPAR-γ和PGC-1α.
结合HHC和NADPH氧化酶抑制进一步降低了增殖,迁移,炎症和ROS.

结论:

HHC通过抑制Ang II诱导的VSMC功能障碍来进行心血管保护.
机制包括抑制NADPH氧化酶介导的ROS生成和增强PPAR-γ/PGC-1α信号传递.
HHC在动脉样硬化和高血压等心血管疾病中显示出治疗潜力.

关键词:

ангиотензин II 的使用六氧化水库尔库.这是一种炎症炎症炎症炎症.移民移民迁移迁移它们的扩散和扩散.血管光滑肌肉细胞细胞

更多相关视频

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro

Published on: February 15, 2022

相关概念视频

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Action of β1 Blockers

Antihypertensive Drugs: Action of β₁ Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...